Pulse Biosciences, Inc. (PLSE)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$53.24-2.69%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · PLSE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 23.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 25 industry peers · Company calendar date is not available
PLSE — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter ended June 30, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference. This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…
Why it matters: A successful redemption can increase the company's money. This can make investors more confident.
Supportive ifMost of the 200% warrants are used before the July 13, 2026 deadline.
Worry ifFew or no 200% warrants are exercised before the deadline.
Why it matters: More sites may help speed up enrollment. This could confirm the nPulse technology.
Supportive ifThe company will add more sites for the NANOPULSE-AF study.
Worry ifNo new sites are added for the NANOPULSE-AF study.
Why it matters: More revenue from nPulse products shows the market likes them. This suggests future growth.
Supportive ifRevenue from nPulse products exceeds $0.4 million in Q2 2026.
Worry ifRevenue from nPulse products remains below $0.4 million in Q2 2026.
Why it matters: Earnings results will show financial health and progress. This can affect how investors feel.
Watch forQ2 earnings show improvement in revenue and reduced net loss compared to Q1.
Also watch forQ2 earnings show more revenue loss or a bigger net loss.
Why it matters: Finishing enrollment shows good progress in the key study for the cardiac catheter. This may lead to new regulations and market chances.
Supportive ifEnrollment in the NANOPULSE-AF study is done by early Q4 2026 as planned.
Worry ifEnrollment completion is delayed beyond early Q4 2026.
Why it matters: This shows strong progress in product development and making money.
Supportive ifQ2 revenue over $500,000 would confirm good product development.
Worry ifQ2 revenue below $500,000 shows slow progress.
Why it matters: A better leadership team can help with strategy and execution.
Supportive ifAnnouncement of new leadership team members or roles before the next earnings date.
Worry ifNo changes to the leadership team announced before the next earnings date.
Why it matters: Better cash flow means better management of expenses.
Supportive ifCash from operating activities reported at less than -$10M would show progress.
Worry ifCash from operating activities remains at -$14.6M or worse.
Why it matters: Updates on trial progress can change how investors view nPulse technology.
Watch forGood news on trial progress or patient outcomes may come during the earnings call.
Also watch forBad news or worries about the trial's progress may come during the earnings call.
Why it matters: Good cash flow management is key for keeping operations going. It also funds clinical trials.
Worry ifCash used in operations drops from $18.7 million in Q2.
Less concerning ifCash used in operations rises above $18.7 million in Q3.
Why it matters: A successful CE Mark submission would prove the technology in Europe. This would help future sales.
Supportive ifCE Mark submission for nPulse technology occurs in the second half of 2026.
Worry ifSubmission for CE Mark is delayed beyond 2026.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$279 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $572 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,651 loss on $10,000 · 36.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.